US health secretary announces plan to address psychiatric medication overprescribing
Health and Human Services Secretary Robert F. Kennedy Jr. has unveiled a plan aimed at curbing the “overprescribing” of psychiatric medications while advocating for alternative treatment options and the right to discontinue medications when necessary, reports BritPanorama.
During a summit at the MAHA Institute on mental health, Kennedy stated, “Today, we take clear and decisive action to confront our nation’s mental health crisis by addressing the overuse of psychiatric medications, especially among children. We will support patient autonomy, require informed consent and shared decision-making, and shift the standard of care toward prevention, transparency, and a more holistic approach to mental health.”
This initiative aligns with ongoing discussions among psychiatric professionals aimed at enhancing research and training regarding the appropriate circumstances for discontinuing medications. Recent guidelines issued by the American Society of Clinical Psychopharmacology in February emphasize these considerations.
While some experts in psychiatry have welcomed the federal government’s efforts to improve mental health care, there are concerns about potential overemphasis on the issue of overprescribing, particularly in light of existing barriers to access for mental health services.
Kennedy has been a prominent critic of psychiatric medications since his appointment last year, labeling them as overused and linking them to various societal issues, including violence and severe risks during pregnancy. Despite these claims, the US Food and Drug Administration has recognized many of these medications as generally safe and effective for various mental health disorders.
Overprescribing is defined as the practice of clinicians prescribing medications when they may not be necessary and failing to consider nonmedication interventions. This includes scenarios where a patient might continue taking ineffective medications beyond the necessary duration.
Dr. Joseph F. Goldberg, a clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai, explained that deprescribing means discontinuing any treatment that does not demonstrate a clear benefit or whose adverse effects outweigh its efficacy.
Dr. Jonathan Alpert of Montefiore Medical Center highlighted the importance of balancing concerns regarding both overprescribing and underprescribing in psychiatric medicine, similar to debates surrounding other types of medication.
For the new initiatives, HHS aims to collaborate on evaluating prescription patterns for psychiatric drugs and their benefits and potential harms. This includes promoting alternative treatments such as therapy, dietary changes, and physical activity, according to a recent news release.
The department also plans to focus on education, outreach, and policy actions to enhance the influence of research on clinical practices.
However, Dr. Theresa Miskimen Rivera, president of the American Psychiatric Association, cautioned against framing mental health issues solely in terms of overmedicalization, pointing out that it simplifies a complex problem.
Remaining gaps in care
Experts warn that focusing heavily on overprescribing may overshadow the significant number of individuals lacking access to care for serious mental health conditions. Goldberg emphasized that depression remains the leading cause of disability globally, with a concerningly low percentage of individuals receiving adequate counseling or therapy.
Despite the discussions around overprescribing, the gap in care for mental health remains prominent, with only about 40% of adults and adolescents with depression having accessed appropriate support in recent years.
While Rivera concurs that mental health care is unevenly distributed, she highlights the need for comprehensive clinical assessments and collaborations between patients and providers to create effective care plans.
Amid ongoing concerns regarding medication, Rivera stressed the importance of not discontinuing treatment without physician oversight, underlining the risks associated with self-initiated changes in medication.
“Don’t do it without physicians being involved,” she advised.
